𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Long term safety and efficacy of donepezil in the treatment of dementia in Alzheimer's disease in adults with Down syndrome: open label study

✍ Scribed by V. P. Prasher; C. Adams; R. Holder

Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
40 KB
Volume
18
Category
Article
ISSN
0885-6230

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of donepezil over 3
Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease
✍ A. Burns; S. Gauthier; C. Perdomo 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 1 views

## Abstract ## Objective This 132‐week, open‐label extension study assessed the long‐term efficacy and safety of donepezil in 579 patients with mild to moderate Alzheimer's disease (AD) who had previously participated in a 24‐week double‐blind study of 5 or 10 mg/day donepezil __vs__ placebo. ##

Review of donepezil, rivastigmine, galan
Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population
✍ V. P. Prasher 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 2 views

## Abstract The management of dementia in Alzheimer's disease has dramatically changed since the development of anti‐dementia drugs. However, there is limited information available regarding the bio‐medical aspects of the differing drugs; particularly relating to adults with intellectual disability

The long-term efficacy and tolerability
The long-term efficacy and tolerability of donepezil in patients with vascular dementia
✍ David Wilkinson; Gustavo Róman; Stephen Salloway; Jane Hecker; Karyn Boundy; Din 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 214 KB 👁 1 views

## Abstract ## Objective To determine the long‐term tolerability and efficacy of donepezil in patients with vascular dementia (VaD). ## Methods International, multicentre, open‐label, 30‐week extension study of two 24‐week, randomised, double‐blind, placebo‐controlled studies. Participants were